Abstract
Regulation of B-cell development and activation is imperative to the myriad of activities that perpetuate humoral immunity. This T-cell dependent immune mechanism often relies upon the maintenance of T-cell tolerance, such that the maturity of the antigen-presentating cell, its function and molecular mimicry are contributing factors. Recent findings have implicated the involvement of the B-cell and their corresponding surface co-receptors in regulating autoimmune disease. One candidate receptor, PECAM-1, has demonstrated the ability to downregulate both B and T-cell signalling pathways. The deletion of PECAM-1 in mice has led to a hyper-responsive B-cell phenotype with abnormal Bcell development. Additionally, in vivo functional studies have found that absence of PECAM-1 results in an increased susceptibility to autoimmune disorders of encephalomyelitis and Type I hypersensitivity reactions. Taken together, these findings indicate that PECAM-1 may have an important role in maintaining B-cell tolerance and regulatory function in preventing the onset of autoimmune disease. Elucidating the mechanisms of PECAM-1 function in autoimmune disorders could facilitate development of novel therapeutics.
Keywords: PECAM-1, autoimmune disease, B-cell, T-cell
Current Pharmaceutical Design
Title: Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Volume: 10 Issue: 2
Author(s): Mae-Xhum Wong and Denise E. Jackson
Affiliation:
Keywords: PECAM-1, autoimmune disease, B-cell, T-cell
Abstract: Regulation of B-cell development and activation is imperative to the myriad of activities that perpetuate humoral immunity. This T-cell dependent immune mechanism often relies upon the maintenance of T-cell tolerance, such that the maturity of the antigen-presentating cell, its function and molecular mimicry are contributing factors. Recent findings have implicated the involvement of the B-cell and their corresponding surface co-receptors in regulating autoimmune disease. One candidate receptor, PECAM-1, has demonstrated the ability to downregulate both B and T-cell signalling pathways. The deletion of PECAM-1 in mice has led to a hyper-responsive B-cell phenotype with abnormal Bcell development. Additionally, in vivo functional studies have found that absence of PECAM-1 results in an increased susceptibility to autoimmune disorders of encephalomyelitis and Type I hypersensitivity reactions. Taken together, these findings indicate that PECAM-1 may have an important role in maintaining B-cell tolerance and regulatory function in preventing the onset of autoimmune disease. Elucidating the mechanisms of PECAM-1 function in autoimmune disorders could facilitate development of novel therapeutics.
Export Options
About this article
Cite this article as:
Wong Mae-Xhum and Jackson E. Denise, Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders, Current Pharmaceutical Design 2004; 10 (2) . https://dx.doi.org/10.2174/1381612043453504
DOI https://dx.doi.org/10.2174/1381612043453504 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Glutamate and Multiple Sclerosis
Current Medicinal Chemistry Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry The Translocator Protein 18 kDa (TSPO) and Its Role in Mitochondrial Biology and Psychiatric Disorders
Mini-Reviews in Medicinal Chemistry Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention
Current Drug Targets Potential Applications of Vasoactive Intestinal Peptide-Based Therapies on Transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry